Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Stock Offering Nets $27.7M

NEW YORK (GenomeWeb News) – Nanosphere has closed a public offering of common stock that has raised net proceeds of around $27.7 million.

The Northbrook, Ill.-based molecular diagnostics firm launched the offering last week. It sold 17,250,000 common shares at $1.75 per share, including 2,250,000 shares that made up the over-allotment option, which was exercised by the underwriters in full.

Nanosphere said that it will use the proceeds for general corporate purposes and working capital.

The company ended the second quarter with $32 million in cash and cash equivalents. In May it raised $4.7 million in net proceeds from a direct offering of its stock.

In Wednesday afternoon trade on the Nasdaq, shares of Nanosphere were down 2 percent at $1.87.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.